~~<i id='C7994BDCE8'><strike id='C7994BDCE8'><tt id='C7994BDCE8'><pre id='C7994BDCE8'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

Wikipedia

author：Wikipedia 2025-09-10 05:02:40 - browse：89

Yichuan Cao/Sipa USA via AP Images

Gilead Sciences said Monday that Trodelvy, its “smart-bomb” medicine that combines an antibody with chemotherapy, did not significantly extend the lives of patients with metastatic non-small cell lung cancer when given after a first treatment failed.

The result, from a closely watched study called Evoke-01, will be seen as a disappointment by investors and oncologists alike.

Drugs like Trodelvy, known as antibody drug conjugates, are one of the hottest areas in oncology. The idea is that these medicines combine an antibody, which is triggered when it binds to a protein on a cancer cell, with a “payload” of chemotherapy that poisons the cancer.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Apple Watch's A

focus

explore

entertainment

hotspot

focus

LaShyraNolenisthefirstinherfamilytogetabachelorsofsciencedegreeandtoattendmedicalschool.CourtesyGret

WSS

Lupron, used to halt puberty in children, may cause lasting health problems

Grandmother of French teen shot dead by police officer pleads with rioters to stop the violence

Skip the lead apron during X

Use wet bulb globe temperature, not heat index, to protect workers

What nurses really want: sufficient staffing for patient care

Vertex cell therapy lets patients with type 1 diabetes stop insulin

knowledge

Wikipedia

focus

BioMarin wins approval for gene therapy to treat hemophilia A

Elevance, private equity launch primary care company

Malaria cases in Florida and Texas: Here’s what you need to know

Study: AI not yet building 'n

Sports medicine is finally prioritizing gender equality

How to improve immunocompromised access to mAb treatments

Medicare proposal to cover medical devices draws a mixed reaction

Use doctors trained outside the U.S. to ease the physician shortage

Medicare details structure of new drug price negotiation program

Use wet bulb globe temperature, not heat index, to protect workers

explore

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

Readout Newsletter: Sanofi, Novavax, Maze x Shionogi news

Beware reading your test results before your doctor does

Study: People of West African ancestry at greater risk of cardiac amyloidosis

Brain worms: The science behind RFK Jr.'s parasitic infection

entertainment

hotspot

hotspot

focus